Gillies Clare L, Abrams Keith R, Lambert Paul C, Cooper Nicola J, Sutton Alex J, Hsu Ron T, Khunti Kamlesh
Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Leicester LE1 7RH.
BMJ. 2007 Feb 10;334(7588):299. doi: 10.1136/bmj.39063.689375.55. Epub 2007 Jan 19.
To quantify the effectiveness of pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance.
Medline, Embase, and the Cochrane library searched up to July 2006. Expert opinions sought and reference lists of identified studies and any relevant published reviews checked.
Randomised controlled trials that evaluated interventions to delay or prevent type 2 diabetes in individuals with impaired glucose tolerance.
21 trials met the inclusion criteria, of which 17, with 8084 participants with impaired glucose tolerance, reported results in enough detail for inclusion in the meta-analyses. From the meta-analyses the pooled hazard ratios were 0.51 (95% confidence interval 0.44 to 0.60) for lifestyle interventions v standard advice, 0.70 (0.62 to 0.79) for oral diabetes drugs v control, 0.44 (0.28 to 0.69) for orlistat v control, and 0.32 (0.03 to 3.07) for the herbal remedy jiangtang bushen recipe v standard diabetes advice. These correspond to numbers needed to treat for benefit (NNTB) and harm (NNTH) of 6.4 for lifestyle (95% credible interval, NNTB 5.0 to NNTB 8.4), 10.8 for oral diabetes drugs (NNTB 8.1 to NNTB 15.0), 5.4 for orlistat (NNTB 4.1 to NNTB 7.6), and 4.0 for jiangtang bushen (NNTH 16.9 to NNTB 24.8).
Lifestyle and pharmacological interventions reduce the rate of progression to type 2 diabetes in people with impaired glucose tolerance. Lifestyle interventions seem to be at least as effective as drug treatment.
量化药物和生活方式干预对糖耐量受损人群预防或延缓2型糖尿病的有效性。
检索截至2006年7月的Medline、Embase和Cochrane图书馆。征求专家意见并检查已识别研究的参考文献列表以及任何相关发表的综述。
评估干预措施以延缓或预防糖耐量受损个体发生2型糖尿病的随机对照试验。
21项试验符合纳入标准,其中17项试验有8084名糖耐量受损参与者,报告的结果足够详细可纳入荟萃分析。从荟萃分析中得出,生活方式干预与标准建议相比的合并风险比为0.51(95%置信区间0.44至0.60),口服降糖药与对照相比为0.70(0.62至0.79),奥利司他与对照相比为0.44(0.28至0.69),中药降糖补肾方与标准糖尿病建议相比为0.32(0.03至3.07)。这些对应于有益治疗所需人数(NNTB)和有害治疗所需人数(NNTH),生活方式干预为6.4(95%可信区间,NNTB 5.0至NNTB 8.4),口服降糖药为10.8(NNTB 8.1至NNTB 15.0),奥利司他为5.4(NNTB 4.1至NNTB 7.6),降糖补肾方为4.0(NNTH 16.9至NNTB 24.8)。
生活方式和药物干预可降低糖耐量受损人群进展为2型糖尿病的发生率。生活方式干预似乎至少与药物治疗一样有效。